Navigation Links
Late Breaking Clinical Trials Presented at HFSA 13th Annual Scientific Meeting
Date:9/14/2009

BOSTON, Sept. 14 /PRNewswire/ -- The 13th Annual Scientific Meeting of the Heart Failure Society of America (HFSA) today featured four late breaking clinical trials at the Hynes Convention Center in Boston. The three-day meeting serves as a forum for heart failure specialists to present research findings and advances in treatment and addresses emerging trends in research and new developments in the approach to treating heart failure patients. Four late breaking trials were presented today:

  • Improving evidence based care for heart failure in outpatient cardiology practices: Primary results of IMPROVE HF. This trial tested the effect of a practice specific performance improvement intervention on quality measure in pts with HF in outpatient cardiology practices. The IMPROVE HF initiative resulted in substantial improvements in use of evidence-based therapies in eligible patients with systolic HF in outpatient cardiology practices. Implementation of a defined and scalable practice specific intervention enhances use of guideline-recommended HF therapies demonstrated to improve outcomes.
  • Reduction in the risk of heart failure with preventative cardiac resynchronization therapy: MADIT - CRT Trial. This trial was designed to determine if prophylactic CRT with defibrillator would reduce the primary endpoint in all cause mortality or HF events (IV diuretic therapy or hospitalization for HF), whichever occurred first, when compared to patients receiving only an implanted cardiac defibrillator. The results of MADIT-CRT suggest that the use of CRT in asymptomatic or mildly symptomatic cardiac patients with a reduced EF and wide QRS complex is associated with a significant 29% decrease in the risk of death or HF. The benefit of CRT-D in this population was driven by a reduction in heart failure events.
  • Superior performance of intrathoracic impedance-derived fluid index versus daily weight monitoring in HF patients: Results of the FAST trial. This trial focused on comparing the relative sensitivity and unexplained detection rate of changes in daily weights vs. intrathoracic impedance changes. The trial concluded that the sensitivity and unexplained detection rate of an intrathoracic fluid index were superior to those for acute weight changes in HF patients with implantable devices. Intrathoracic impedance monitoring represents a positive addition to our armamentarium for managing HF and should be considered for routine use in patients with implanted devices with this feature in addition to daily weight monitoring.
  • Effects of rolofylline, a selective adenosine A1 receptor antagonist, in patients hospitalized for acute decompensated heart failure and renal impairment: Findings from the PROTECT study. This trial was designed to test the hypothesis that the selective A1 adenosine receptor antagonist rolofylline would safely improve HF signs and symptoms, reduce the risk of worsening renal function and reduce morbidity and mortality when used with IV loop diuretics in subjects with ADHF, volume overload and renal impairment. Surprisingly and disappointedly, rolofylline was not associated with an improvement in the primary endpoint or the two secondary endpoints including renal function. This trial, the largest to date in ADHF, will require further analysis to help investigators develop new strategies for the important but complicated condition of ADHF.

"Each year we discover new and innovative treatments for patients living with heart failure," said Dr. Douglas Mann, HFSA President. "It is important for the medical community to continue to utilize science and clinical medicine to improve care that we provide to patients with heart failure."

For a complete list of annual meeting sessions or for details on attending the conference, call (617) 226-7183 or visit www.hfsa.org and click on Annual Scientific Meeting. There is no registration fee for accredited journalists. Interview areas will be available on-site in addition to a fully-staffed press room with phone and internet accessibility.

About Heart Failure

Heart failure is a progressive condition in which the heart muscle becomes weakened after it is injured, most commonly from heart attack or high blood pressure, and gradually loses its ability to pump enough blood to supply the body's needs. Many people are not aware they have heart failure because the symptoms are often mistaken for signs of getting older. Heart failure affects from 4.6 to 4.8 million individuals in the United States. Demographic and clinical evidence strongly suggests that the prevalence of heart failure will increase throughout the next decade. Ten to 15 years ago heart failure was considered a "death sentence;" however, recent advances in treatment have shown that early diagnosis and proper care in early stages of the condition are key to slowing, stopping or in some cases reversing progression, improving quality of life, and extending life expectancy. For more information on heart failure, please visit www.abouthf.org.

About the Heart Failure Society of America

The Heart Failure Society of America (HFSA) is a nonprofit educational organization, founded in 1994 as the first organized association of heart failure experts. Today HFSA has over 1,500 members and provides a forum for all those interested in heart function, heart failure research and patient care. The Society also serves as a resource for governmental agencies (FDA, NIH, NHLBI, CMS). The HFSA Annual Scientific Meeting is designed to highlight recent advances in the development of strategies to address the complex epidemiological, clinical and therapeutic issues of heart failure. Additional information on HFSA can be found at www.hfsa.org.


'/>"/>
SOURCE The Heart Failure Society of America
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. MultiVu Video Feed: POSITIVE PHASE 3 TRIAL DATA FOR INVESTIGATIONAL NEW MIGRAINE TREATMENT PRESENTED IN LATE-BREAKING SESSION AT 14th ANNUAL INTERNATIONAL HEADACHE SOCIETY CONGRESS
2. MAP Pharmaceuticals Analysis of Positive Phase 3 LEVADEX(TM) Data To Be Presented in Late-Breaking Session at 14th Congress of the International Headache Society
3. UNT Health Science Centers Groundbreaking Research Applied to Protecting Brain After Traumatic Injury
4. Stand Up To Cancer Awards $73.6 Million for Novel, Groundbreaking Cancer Research
5. Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen
6. Impulse Dynamics Announces Pivotal Results at the American College of Cardiology Annual Meeting Late-Breaking Session
7. Results From Efficacy and Safety Study of Cortheras Relaxin in Acute Heart Failure to be Presented at Late-Breaking Clinical Trials Session at ACC 58th Annual Scientific Session
8. Lake Hospital System Receives $60,000 Grant for Groundbreaking Music Therapy Study
9. Atritech to Participate in Late-Breaking Clinical Trial Presentation at American College of Cardiology Meeting
10. Groundbreaking Paper Publishes Long Term Results of a Successful Phase I Clinical Trial Using Autologous Neural Stem Cells to Treat Parkinsons Disease
11. Late-Breaking Data Highlighting Research Advances in Several Blood Disorders to Be Presented At the American Society of Hematology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... , Feb. 5, 2016  Syneron Medical Ltd. ... device company, announced today that William Griffing ... America, is scheduled to participate in the Leerink ... on February 11, 2016 in New ... institutional investors to meet with the Mr. Griffing ...
(Date:2/5/2016)... 5, 2016 ... the "Global Musculoskeletal Partnering 2010-2016: Deal ... to their offering. --> ... the "Global Musculoskeletal Partnering 2010-2016: Deal ... to their offering. --> ...
(Date:2/5/2016)... , Feb. 5, 2016  Zimmer Biomet Holdings, ... of the previously announced underwritten secondary offering of 11,027,558 ... stockholders, consisting of affiliates of Blackstone and Goldman Sachs. ... an initial price of $96.45 per share. The selling ... offering.  Neither Zimmer Biomet nor any of its directors, ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... February 08, 2016 , ... Brenntag Specialties, Inc.(BSI) , ... Food & Beverage and Dietary Supplement market segments across the ... USA geographies east of the Rocky Mountains since 2012. Consistent performance in ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... LA, celebrates the beginning of a new charity campaign. As part of their ... Special Advocates (CASA). In the belief that children deserve a voice, and in ...
(Date:2/8/2016)... ... 2016 , ... A man who has struggled to quit smoking, a man who has struggled ... to find solutions to his problems – and he did. Now Nabat, a serial entrepreneur ... introduce his breakthrough inventions to the world and better people's lives. His own experience with ...
(Date:2/8/2016)... ... ... If you are feeling that your clothes are a tad snug, the ... Center for Disease Control and Prevention (CDC), 34.9% of U.S. adult women are overweight. ... some of the leading causes of preventable death. February is heart health month ...
(Date:2/8/2016)... Hilton Head Island, SC (PRWEB) , ... February 08, 2016 , ... ... Head and surrounding areas with a vital new community enrichment program, has teamed up ... to local women and children suffering from intimate abuse. To support all those victimized ...
Breaking Medicine News(10 mins):